(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 February 2007 (08.02.2007)

PCT

(10) International Publication Number
WO 2007/014927 A3

(51) International Patent Classification:
C07D 417/04 (2006.01) *A61K 31/517* (2006.01)
C07D 239/72 (2006.01) *A61P 31/12* (2006.01)

(21) International Application Number:
PCT/EP2006/064822

(22) International Filing Date: 28 July 2006 (28.07.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05107057.1 29 July 2005 (29.07.2005) EP
06113097.7 25 April 2006 (25.04.2006) EP

(71) Applicants *(for all designated States except US)*: **TIBOTEC PHARMACEUTICALS LTD.** [IE/IE]; Eastgate Village, Eastgate, Little Island, Co Cork (IE). **MEDIVIR AB** [SE/SE]; Lunastigen 7, S-141 44 Huddinge (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **RABOISSON, Pierre, Jean-Marie, Bernard** [FR/BE]; Sint Pancratiuslaan 26, B-1933 Sterrebeek (BE). **DE KOCK, Herman, Augustinus** [BE/BE]; Wolfseind 10, B-2370 Arendonk (BE). **HU, Lili** [NL/BE]; Rik Woutersstraat 21, B-2800 Mechelen (BE). **SIMMEN, Kenneth, Alan** [GB/BE]; Boterbloemenlaan 35, B-3080 Tervuren (BE). **LINDQUIST, Karin, Charlotta** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddingen (SE). **LINDSTRÖM, Mats, Stefan** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddingen (SE). **BELFRAGE, Anna, Karin, Gertrud, Linnea** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **WÄHLING, Horst, Jürgen** [DE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **NILSSON, Karl, Magnus** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **SAMUELSSON, Bengt, Bertil** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **ROSENQUIST, Åsa, Annica, Kristina** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **SAHLBERG, Sven, Crister** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **WALLBERG, Hans, Kristian** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **KAHNBERG, Pia, Cecilia** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). **CLASSON, Björn, Olof** [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE).

(74) Agent: **DAELEMANS, Frank**; Tibotec-Virco Comm. VA, J & J Patent Law Department, Generaal De Wittelaan L 11b 3, B-2800 Mechelen (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

[Continued on next page]

(54) Title: MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS



(I)

(57) Abstract: Compounds of the formula (I), and N-oxides, salts, and stereoisomers thereof wherein A is OR^1, $NHS(=O)_pR^2$; wherein; R^1 is hydrogen, C_1-C_6alkyl, C_0-C_3alkylenecarbocyclyl, C_0-C_3alkylene-heterocyclyl; R^2 is C_1-C_6alkyl, C_0-C_3alkylenecarbocyclyl, C_0-C_3alkyleneheterocyclyl; p is independently 1 or 2; n is 3, 4, 5 or 6; ---- deonotes an optional double bond; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; Rq is H or when L is CRz, Rq can also be C_1-C_6alkyl; Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C_1-C_6 alkyl, C_1-C_6alkoxy, hydroxyl, halo, haloC_1-C_6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C_1-C_6alkyl-carbonylamino, C_0-C_3alkylenecarbocyclyl and C_0-C_3 alkyleneheterocyclyl; R^5 is hydrogen, C_1-C_6alkyl, C_1-C_6alkoxyC_1-C_6alkyl or C_3-C_7cycloalkyl; R^6 is hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, C_0-C_3alkylenecarbocyclyl, C_0-C_3alkyleneheterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV.

WO 2007/014927 A3

(88) Date of publication of the international search report:
29 November 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.